Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Microarray Analysis

By Drug Discovery Trends Editor | April 29, 2010

Illumina, Inc. announced shipment of HiScanSQ, the first instrument to integrate microarray analysis and next-generation sequencing in a modular design that can evolve with changing research needs. HiScanSQ is designed for smaller core labs that don’t want to purchase separate platforms to run sequencing and microarray experiments; groups that primarily run arrays but are looking to move into sequencing for the first time; and facilities that run both arrays and capillary electrophoresis sequencing and are looking to add high-throughput sequencing.

The HiScanSQ system has two components: the HiScan Reader, a high-performance array scanner that can also image sequencing flow cells and the SQ Module, an add-on fluidics device that enables genomic-scale sequencing. The publication-proven HiScan Reader functions independently as a high-speed, precision micro-array scanner for Illumina’s BeadArray products. With the SQ module, the system switches to perform Illumina’s sequencing-by-synthesis (SBS), the most widely adopted next-generation sequencing technology, generating 50 Gb of data per paired-end flow cell. Together, these complementary technologies provide a powerful approach to genetic discovery and validation.

“The idea behind the HiScanSQ platform is to give people flexibility,” said Tristan Orpin, senior vice president, Commercial Operations at Illumina. “The falling cost of sequencing has made arrays and sequencing complementary, so many core labs are looking for a system that will allow them to perform some initial discovery with arrays, and then use sequencing to further characterize or validate the results in-house. For instance, researchers can leverage targeted resequencing to follow-on their genome wide association study or transition between array-based and sequencing-based gene expression.”

Researchers can minimize hands-on time through a number of user interface features that automate and streamline HiScanSQ workflow including a touch screen interface, pre-configured plug and play reagents, and data analysis software to allow users to visually integrate sequencing and array data.

Illumina, Inc.


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50